Detection Of Mycobacterium Tuberculosis and Rifampicin Resistance Using GeneXpert MTB/RIF Assay: GeneXpert MTB/RIF: Detecting Tuberculosis and Rifampicin Resistance

Fatima  Maqsood; Muhammad Tahir  Khan; Aysha  Siddique; Fatima  Aftab; Zarafshan  Asjad; Syeda Yusra  Fatima

doi:10.69750/dmls.02.05.0122

Authors

Fatima Maqsood Institute of Molecular Biology and Biotechnology (IMBB),CRiMM, The University of Lahore, Lahore Pakistan. Author
Muhammad Tahir Khan Institute of Molecular Biology and Biotechnology (IMBB),CRiMM, The University of Lahore, Lahore Pakistan. Author https://orcid.org/0000-0003-1158-2133
Aysha Siddique Institute of Molecular Biology and Biotechnology (IMBB),CRiMM, The University of Lahore, Lahore Pakistan. Author
Fatima Aftab Institute of Molecular Biology and Biotechnology (IMBB),CRiMM, The University of Lahore, Lahore Pakistan. Author
Zarafshan Asjad Institute of Molecular Biology and Biotechnology (IMBB),CRiMM, The University of Lahore, Lahore Pakistan. Author
Syeda Yusra Fatima Institute of Molecular Biology and Biotechnology (IMBB),CRiMM, The University of Lahore, Lahore Pakistan. Author

DOI:

https://doi.org/10.69750/dmls.02.05.0122

Keywords:

Tuberculosis, Mycobacterium tuberculosis, GeneXpert, Rifampicin resistance

Abstract

Background: Tuberculosis (TB) remains a major global health challenge, especially in developing countries, due to its high morbidity and mortality rates. The emergence of rifampicin-resistant Mycobacterium tuberculosis (MTB) strains further complicates disease management and control strategies.

Objective: To evaluate the diagnostic performance of the GeneXpert MTB/RIF assay in detecting MTB and rifampicin resistance among suspected TB patients in Lahore, Pakistan.

Methods: This cross-sectional study analyzed 865 sputum samples from patients presenting with TB symptoms at selected hospitals in Lahore. The GeneXpert MTB/RIF assay was employed for simultaneous detection of MTB and rifampicin resistance. Demographic data, including age and gender, were also recorded and analyzed.

Results: Out of 865 patients, 192 (22.19%) tested positive for MTB. The majority of positive cases were males and individuals aged 46 to 65 years. Rifampicin resistance was identified in 41.66% of the MTB-positive cases, indicating a high prevalence of drug-resistant TB. The GeneXpert system demonstrated rapid and reliable detection capabilities, significantly reducing diagnostic delays.

Conclusion: The GeneXpert MTB/RIF assay proves to be a valuable diagnostic tool in TB-endemic regions, offering timely detection of both MTB and rifampicin resistance. The findings highlight the urgent need for improved biosafety measures, regular drug susceptibility testing, and strengthened public health strategies to contain the spread of drug-resistant TB.

Downloads

Download data is not yet available.

Author Biography

Muhammad Tahir Khan, Institute of Molecular Biology and Biotechnology (IMBB),CRiMM, The University of Lahore, Lahore Pakistan.

Associate Researcher, Department of Clinical Laboratory, Guangzhou Medical University, Guangzhou, China

References

Guan Z, Han X, Huang W, Wang X, Wang H, Fan Y, et al. Construction and application of a heterogeneous quality control library for the Xpert MTB/RIF assay in tuberculosis diagnosis. Front Cell Infect Microbiol. 2023;13:1128337. doi:10.3389/fcimb.2023.1128337

Bates M, O'Grady J, Maeurer M, Tembo J, Chilukutu L, Chabala C, et al. Assessment of the Xpert MTB/RIF assay for diagnosis of tuberculosis with gastric lavage aspirates in children in sub-Saharan Africa: a prospective descriptive study. Lancet Infect Dis. 2013;13(1):36–42. doi:10.1016/S1473-3099(12)70245-1

Bagcchi S. WHO’s global tuberculosis report 2022. Lancet Microbe. 2023;4(1):e20. doi:10.1016/S2666-5247(22)00359-7

Hermans S, Caldwell J, Kaplan R, Cobelens F, Wood R. The impact of the roll out of rapid molecular diagnostic testing for tuberculosis on empirical treatment in Cape Town, South Africa. Bull World Health Organ. 2017;95(8):554–63. doi:10.2471/BLT.16.185314

Tolani MP, D’Souza DTB, Mistry NF. Drug resistance mutations and heteroresistance detected using the GenoType MTBDRplus assay and their implication for treatment outcomes in patients from Mumbai, India. BMC Infect Dis. 2012;12:8. doi:10.1186/1471-2334-12-8

Quincó P, Bührer Sékula S, Brandão W, Monte R, Souza SL, Saraceni V, et al. Increased sensitivity in diagnosis of tuberculosis in HIV-positive patients through the small membrane filter method of microscopy. J Clin Microbiol. 2013;51(9):2921–5. doi:10.1128/JCM.01114-13

van Rie A, Page-Shipp L, Scott L, Sanne I, Stevens W. Xpert MTB/RIF for point-of-care diagnosis of TB in high HIV-burden, resource-limited countries: hype or hope? Expert Rev Mol Diagn. 2010;10(7):937–46. doi:10.1586/erm.10.66

Maqsood R, Duffy SC, Bin Rashid H, Gill SS, Jabeen C, Arshad N, et al. Molecular detection and characterization of the Mycobacterium tuberculosis complex subspecies responsible for bovine tuberculosis in Punjab, Pakistan. Microbiol Spectr. 2024;12(2):e02692-23. doi:10.1128/spectrum.02692-23

Kay AW, Fernández LG, Takwoingi Y, Eisenhut M, Detjen AK. Xpert MTB/RIF and Xpert MTB/RIF Ultra assays for active tuberculosis and rifampicin resistance in children. Cochrane Database Syst Rev. 2020;(8):CD013359. doi:10.1002/14651858.CD013359.pub2

Kiran M, Naqvi SMA, Iqbal HA, Butt ARZ, Shafi N. The diagnostic performance of fluorescent microscopy and MTB/RIF assay GeneXpert in pulmonary tuberculosis at a tertiary care hospital of Lahore. Pak J Med Health Sci. 2022;16(5):449–52. doi:10.54393/pjmhs.v16i05.4124

Schaaf H, Botha P, Beyers N, Gie R, Vermeulen H, Groenewald P, et al. The 5-year outcome of multidrug-resistant tuberculosis patients in the Cape Province of South Africa. Int J Tuberc Lung Dis. 1996;1(5):718–22.

Wang MQ, Zheng YF, Hu YQ, Huang JX, Yuan ZX, Wu ZY, et al. Diagnostic accuracy of Xpert MTB/RIF Ultra for detecting pulmonary tuberculosis and rifampicin resistance: a systematic review and meta-analysis. Eur J Clin Microbiol Infect Dis. 2025;44(3):681–702. doi:10.1007/s10096-024-04888-7

Feasey NA, Banada PP, Howson W, Sloan DJ, Mdolo A, Boehme C, et al. Evaluation of Xpert MTB/RIF for detection of tuberculosis from blood samples of HIV-infected adults confirms M. tuberculosis bacteremia as an indicator of poor prognosis. J Clin Microbiol. 2013;51(7):2311–6. doi:10.1128/JCM.00519-13

Piersimoni C, Gherardi G, Gracciotti N, Pocognoli A. Comparative evaluation of Xpert MTB/RIF and the new Xpert MTB/RIF Ultra with respiratory and extrapulmonary specimens for tuberculosis case detection in a low-incidence setting. J Clin Tuberc Other Mycobact Dis. 2019;15:100094. doi:10.1016/j.jctube.2019.100094

Yu Y, Kong Y, Ye J, Wang A. Performance of conventional histopathology and GeneXpert MTB/RIF in the diagnosis of spinal tuberculosis from bone specimens: a prospective clinical study. Clin Biochem. 2020;85:33–7. doi:10.1016/j.clinbiochem.2020.06.005

Selfegna S, Alelign A. Detection of Mycobacterium tuberculosis and rifampicin resistance using GeneXpert MTB/RIF assay at Enat Hospital, Central Ethiopia. Tuberc Res Treat. 2022;2022:1250404. doi:10.1155/2022/1250404

Hordofa MW, Adela TB. Prevalence of rifampicin-mono-resistant Mycobacterium tuberculosis among suspected cases attending Yirgalem Hospital. Clin Med Res. 2015;4(3):75–8. doi:10.11648/j.cmr.20150403.12

Asfaw T, Terefe A, Nigus M. Patterns and trends of rifampicin-resistant Mycobacterium tuberculosis and associated factors among presumptive tuberculosis patients at Debre Berhan Referral Hospital. J Biosci Bioeng. 2018;8:339. doi:10.11648/j.jb.20180801.47

Admassu W, Ayelign B, Abebe G, Tadesse M. Detection of Mycobacterium tuberculosis and rifampicin resistance by Xpert MTB/RIF assay among presumptive tuberculosis cases at Jimma University Medical Center, Southwest Ethiopia. PLoS One. 2022;17(1):e0262929. doi:10.1371/journal.pone.0262929

Mekonnen F, Tessema B, Moges F, Gelaw A, Eshetie S, Kumera G. Multidrug-resistant tuberculosis: prevalence and risk factors in districts of Metema and West Armachiho, Northwest Ethiopia. BMC Infect Dis. 2015;15:1–6. doi:10.1186/s12879-015-0785-7

Toroka PR, Majigo MV, Kileo H, Urio L, Mbwana MR, Monah MC, et al. The pattern of rpoB gene mutation of Mycobacterium tuberculosis and predictors of rifampicin resistance detected by GeneXpert MTB/RIF assay in Tanzania. PLoS One. 2024;19(8):e0296563. doi:10.1371/journal.pone.0296563

Toru M, Baye A, Gebeyehu Z, Abebaw A, Reta A. Prevalence, associated factors and rifampicin resistance pattern of pulmonary tuberculosis among HIV-positive patients attending antiretroviral treatment clinic at East Gojjam Zone, Ethiopia. J Clin Tuberc Other Mycobact Dis. 2022;29:100336. doi:10.1016/j.jctube.2022.100336

Asgharzadeh M, Ozma MA, Rashedi J, Poor BM, Agharzadeh V, Vegari A, et al. False-positive Mycobacterium tuberculosis detection: ways to prevent cross contamination. Tuberc Respir Dis (Seoul). 2020;83(3):211–9. doi:10.4046/trd.2020.0064

Listiowati E, Rianti FE. Relationship between knowledge and using personal protective equipment in tuberculosis ward and polyclinic of Hospital X. Mutiara Med J Kedokt Kesehat. 2021;21(1):20–5. doi:10.37505/mmjk.v21i1.772

Helle OMB, Kanthali M, Grønningen E, Hassan S, Purohit MR, Mustafa T. Factors associated with hospitalization and mortality in adult and pediatric extrapulmonary tuberculosis at a tertiary care hospital in Central India. Infect Dis (Lond). 2024;56(12):1080–92. doi:10.1080/23744235.2024.2334546